Investment Bridge, one of Japan's leading IR services companies, has released a “Bridge Report” on CellSeed Inc. (JASDAQ: 7776) reviewing fiscal year December 2013 earnings results and fiscal year December 2014 earnings estimates. Report Highlights * CellSeed believes that regenerative medicine within Japan is entering a period of full scale development and rapid growth. * During fiscal year December 2013, sales rose by 40.0% year-over-year to JPY105 million, and the recurring loss declined to JPY581 from JPY842 million in the previous term. * During fiscal year December 2014, CellSeed will continue to pursue progress in and fortify the three cornerstones of its business based upon its midterm term vision of “creation of a sustainable business model that leverages changes in the external environment.” CellSeed is a leading company in regenerative medicine, which employs the cutting edge technology of “cell sheet engineering” as its technological base for developing new medical treatments that can lead to fundamental changes in the therapy of severe medical conditions worldwide. About Bridge Report: Bridge Report is produced by Investment Bridge Co., Ltd. and provides accurate and objective information about the earnings, business strategies, and other information of publicly traded Japanese companies. Contact: Investment Bridge Co., Ltd. mailto:CellSeed@cyber-ir.co.jp Contributed via: Bloomberg Publisher WEB Service
Bridge Report on CellSeed Inc. Issued: FY12/13 Results and FY12/14 Estimates
Press spacebar to pause and continue. Press esc to stop.